Clinical trials: completed, sponsored by Merck Sharp & Dohme LLC
Arthritis, Rheumatoid
A Study to Evaluate the Effectiveness of Infliximab and Changes in Hand and Wrist Magnetic Resonance Imaging (MRI) in Participants With Active Rheumatoid Arthritis (RA) (P08136)
This is a study to compare the effect of infliximab versus placebo on synovial inflammation as measured by dynamic contrast enhanced (DCE)-MRI of one wrist.
- Trial name
- NCT01313520
- Testing
- Infliximab
- Volunteers
- 61 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypertension
Hyzaar Asia HEAALTH (0954A-950)
The objective of the study is to estimate the percentage of patients who reach blood pressure goal after 8 weeks of treatment with losartan/HCTZ combination.
- Trial name
- NCT00354991
- Testing
- losartan potassium (+) hydrochlorothiazide
- Volunteers
- 437 people
- Sponsor
- Merck Sharp & Dohme LLC
Observation of Neuromuscular Block
Residual Curarization and Its Incidence at Tracheal Extubation (P08194)
This study will assess the residual neuromuscular blockade (NMB) Train-Of-Four (TOF) ratios at tracheal extubation when anesthesiologists have determined that full recovery of neuromuscular function has occurred using standard…
- Trial name
- RECITE (NCT01318382)
- Testing
- TOF-Watch SX® Monitoring of NMB
- Volunteers
- 302 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostate Cancer
Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)
To determine the efficacy and safety of an investigational compound (MK0966) for the prevention of prostate cancer.
- Trial name
- NCT00060476
- Testing
- rofecoxib
- Volunteers
- 15,000 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Temozolomide for Treatment of Brain Metastases From Non-Small Cell Lung Cancer (Study P03247)
The purpose of this study is to demonstrate improvement in overall survival for the combination of whole brain radiation therapy (WBRT) plus temozolomide (TMZ) versus WBRT alone.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Brain Neoplasms
- Trial name
- NCT00076856
- Testing
- Temozolomide
- Volunteers
- 95 people
- Sponsor
- Merck Sharp & Dohme LLC
Osteoarthritis
A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-220)(COMPLETED)
The purpose of this study is to compare the safety and effectiveness of two approved drugs in the treatment of osteoarthritis of the knee.
- Trial name
- NCT00092365
- Testing
- MK0966, rofecoxib
- Volunteers
- 413 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Adenoma
A Study to Evaluate the Effect of MK0966 (Rofecoxib) on the Recurrence of Colorectal Adenomas (0966-122)
This study was to compare the effect of 156 weeks of treatment with MK-0966 (Rofecoxib) versus placebo on the recurrence of colorectal adenomas (growths that occur on the inside (the lining) of the large intestine, also known as…
- Trial name
- NCT00282386
- Testing
- MK0966; Rofecoxib / Duration of Treatment: 156 weeks
- Volunteers
- 2,586 people
- Sponsor
- Merck Sharp & Dohme LLC
Postoperative Pain
A Study of Two Approved Drugs in the Treatment of Post-Bunionectomy Surgery Pain (0966-234)(COMPLETED)
This purpose of this study is to compare the safety and effectiveness of two approved drugs in the treatment of pain following bunionectomy surgery.
- Trial name
- NCT00092378
- Testing
- MK0966, rofecoxib
- Volunteers
- 251 people
- Sponsor
- Merck Sharp & Dohme LLC
Postoperative Pain
A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-190)(COMPLETED)
The purpose of this study is to compare the safety and effectiveness of two approved drugs in the treatment of pain following dental surgery.
- Trial name
- NCT00092339
- Testing
- MK0966, rofecoxib
- Volunteers
- 125 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastases of Central Nervous System, Melanoma
Study to Evaluate the Efficacy and Safety of Temozolomide in Subjects With Brain Metastases of Either Malignant Melanoma, Breast, or Non-small Cell Lung Cancer (P02064)
The study implies a 2 step study design. Patients are enrolled into 3 separate groups for melanoma, breast, and non-small cell lung cancer. In the first step, 21 patients per disease group are enrolled.
- Conditions
- Metastases of Central Nervous System, Melanoma, Breast Neoplasm, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT00831545
- Testing
- Temozolomide
- Volunteers
- 162 people
- Sponsor
- Merck Sharp & Dohme LLC
Osteoarthritis
A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-219)
The purpose of this study is to compare the safety and effectiveness of two approved drugs in the treatment of osteoarthritis of the knee.
- Trial name
- NCT00092352
- Testing
- MK0966, rofecoxib
- Volunteers
- 395 people
- Sponsor
- Merck Sharp & Dohme LLC
Major Depressive Disorder
Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED)
A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression.
- Trial name
- NCT00048594
- Testing
- aprepitant
- Volunteers
- 800 people
- Sponsor
- Merck Sharp & Dohme LLC
Major Depressive Disorder
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073)
A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression.
- Trial name
- NCT00042029
- Testing
- MK0869, aprepitant
- Volunteers
- 324 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Non-Insulin-Dependent
Clinical Study on Sitagliptin for Assessment of Glucose-lowering Effects (0431-045)
A clinical study determines the safety and efficacy of sitagliptin (MK0431) in patients with Type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy
- Trial name
- NCT00758069
- Testing
- sitagliptin phosphate, Comparator: Sitagliptin
- Volunteers
- 80 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type II
Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)
The purpose of this study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.
- Trial name
- NCT00086515
- Testing
- Sitagliptin (MK0431), Metformin, Pioglitazone
- Volunteers
- 701 people
- Sponsor
- Merck Sharp & Dohme LLC
Major Depressive Disorder
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)
A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression.
- Trial name
- NCT00034944
- Testing
- MK0869, aprepitant
- Volunteers
- 495 people
- Sponsor
- Merck Sharp & Dohme LLC
Nausea, Vomiting
Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)
The purpose of this study is to determine the efficacy and tolerability of an investigational drug for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy.
- Conditions
- Nausea, Vomiting, Breast Neoplasms
- Trial name
- NCT00092196
- Testing
- MK0869, aprepitant / Duration of Treatment: 3 days
- Volunteers
- 820 people
- Sponsor
- Merck Sharp & Dohme LLC
Major Depressive Disorder
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)
A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression.
- Trial name
- NCT00035048
- Testing
- aprepitant
- Volunteers
- 540 people
- Sponsor
- Merck Sharp & Dohme LLC
Postoperative Nausea and Vomiting
2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-090)(COMPLETED)
The purpose of this study is to assess the safety and efficacy of 2 doses of an approved drug for a new indication in the prevention of postoperative nausea and vomiting in patients receiving general anesthesia for open abdominal…
- Trial name
- NCT00090155
- Testing
- MK0869, aprepitant, Comparator: ondansetron IV
- Volunteers
- 805 people
- Sponsor
- Merck Sharp & Dohme LLC
Postoperative Nausea and Vomiting
2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091)
The purpose of this study is to assess the safety and efficacy of 2 doses of an approved drug for a new indication in the prevention of postoperative nausea and vomiting in patients receiving general anesthesia for open abdominal…
- Trial name
- NCT00090246
- Testing
- MK0869, aprepitant, Comparator: ondansetron IV
- Volunteers
- 922 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.